Director/PDMR Shareholding

RNS Number : 5868Q

C4X Discovery Holdings PLC

30 November 2016

 

 30 November 2016

This announcement contains inside information

C4X Discovery Holdings plc

("C4XD" or the "Company")

DIRECTOR'S DEALING

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, announces that Dr. Clive Dix, Chief Executive Officer, has today purchased 40,000 ordinary shares of 1 pence each ("Ordinary Shares") a price of £0.97 pence per Ordinary Share.

Director	Ordinary Shares held prior to dealing	Ordinary Shares purchased	Interest in issued share capital (%)	Interest in Ordinary Shares via incentive arrangements	Total interest in issued share capital (%)
Dr. Clive Dix, Chief Executive Officer	1,156,936	40,000	3.20%	145,000	3.59%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr. Clive Dix
2	Reason for the notification
a)	Position/status	Chief Executive Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	1p ordinary shares ISIN GB00BQQ2RV18
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) £0.97p 40,000
d)	Aggregated information	Price(s) Volume(s) £0.97p 40,000
e)	Date of the transaction	30 November 2016
f)	Place of the transaction	London Stock Exchange - AIM

For further information, please contact:

C4X Discovery Holdings plc

Clive Dix, Chief Executive Officer                                                                                          07801 865 803

Zeus Capital Limited

Dan Bate                                                                                                                                   0161 831 1512

Dominic Wilson/Phil Walker                                                                                                 0203 829 5000

Consilium Strategic Communications

Mary-Jane Elliott, Matthew Neal, Melissa Gardiner                                                         0203 709 5700 

About C4X Discovery

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.

C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3®) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.

C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.

The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com

 

END

 

 

DSHEALFEDAAKFFF